Kernal Biologics
Development-stage biotechnology company focused on engineering cells in vivo using targeted lipid nanoparticle delivery of synthetic mRNA and machine-learning-driven mRNA design. The platform combines antibody-functionalized lipid nanoparticles for extra-hepatic, cell-type specific mRNA delivery with data-driven mRNA sequence design to achieve preferential translation in target cell types. Activities described include preclinical in vivo programs for in situ CAR-T programming, process development for scalable mRNA manufacturing, and analytical characterization of targeted mRNA-LNPs.
Industries
Nr. of Employees
small (1-50)
Kernal Biologics
Products
In vivo CAR-T mRNA therapeutic program (preclinical)
Program delivering CAR-encoding mRNA to T cells in vivo to program CAR-T activity without ex vivo cell manufacturing; preclinical data reported showing in vivo B-cell depletion.
Tumor-targeted mRNA-LNP immunotherapy program (preclinical)
Cancer cell-targeting mRNA-LNP program reported to show an improved therapeutic index and efficacy in preclinical solid tumor models.
In vivo CAR-T mRNA therapeutic program (preclinical)
Program delivering CAR-encoding mRNA to T cells in vivo to program CAR-T activity without ex vivo cell manufacturing; preclinical data reported showing in vivo B-cell depletion.
Tumor-targeted mRNA-LNP immunotherapy program (preclinical)
Cancer cell-targeting mRNA-LNP program reported to show an improved therapeutic index and efficacy in preclinical solid tumor models.
Services
Machine-learning-enabled design of mRNA sequences with preferential translation in target cell types to minimize off-target expression.
Formulation and antibody-functionalization of lipid nanoparticles to achieve systemic extra-hepatic delivery to specific tissues and cell types.
Machine-learning-enabled design of mRNA sequences with preferential translation in target cell types to minimize off-target expression.
Formulation and antibody-functionalization of lipid nanoparticles to achieve systemic extra-hepatic delivery to specific tissues and cell types.
Expertise Areas
- mRNA therapeutics design
- Targeted nanoparticle delivery
- In vivo cell programming (in situ CAR-T)
- Machine-learning-driven sequence discovery
Key Technologies
- Synthetic mRNA therapeutics
- Lipid nanoparticle (LNP) delivery
- Antibody-functionalized nanoparticles
- In vitro transcription (IVT) processes
News & Updates
Company to showcase mRNA platform and T-cell-targeted LNPs for in situ CAR T programming at ASGCT 2026 (press release).
Presentation of mRNA platform and pipeline at Bio€quity Europe 2025 (CEO presentation).
Announcement of collaboration with Lilly Gateway Labs to accelerate in vivo cell therapies.
Media coverage referencing the company's mRNA 2.0 platform.
Announcement of $25M Series A financing to advance mRNA 2.0 technology for oncology.
Awarded up to $48 million from ARPA-H to develop lower-cost in vivo CAR T-cell therapies for hematological cancers and autoimmune disease (press release).
Company to showcase mRNA platform and T-cell-targeted LNPs for in situ CAR T programming at ASGCT 2026 (press release).
Presentation of mRNA platform and pipeline at Bio€quity Europe 2025 (CEO presentation).
Announcement of collaboration with Lilly Gateway Labs to accelerate in vivo cell therapies.
Media coverage referencing the company's mRNA 2.0 platform.
Announcement of $25M Series A financing to advance mRNA 2.0 technology for oncology.
Awarded up to $48 million from ARPA-H to develop lower-cost in vivo CAR T-cell therapies for hematological cancers and autoimmune disease (press release).